NZ600482A - Microrna (miRNA)and downstream targets for diagnostic and therapeutic purposes - Google Patents
Microrna (miRNA)and downstream targets for diagnostic and therapeutic purposesInfo
- Publication number
- NZ600482A NZ600482A NZ600482A NZ60048209A NZ600482A NZ 600482 A NZ600482 A NZ 600482A NZ 600482 A NZ600482 A NZ 600482A NZ 60048209 A NZ60048209 A NZ 60048209A NZ 600482 A NZ600482 A NZ 600482A
- Authority
- NZ
- New Zealand
- Prior art keywords
- sprouty1
- fibrosis
- sample
- vitro method
- protein
- Prior art date
Links
- 108091070501 miRNA Proteins 0.000 title 2
- 239000002679 microRNA Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 4
- 230000004761 fibrosis Effects 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000338 in vitro Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 239000000523 sample Substances 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 210000002950 fibroblast Anatomy 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 230000004075 alteration Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000013068 control sample Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108091062762 miR-21 stem-loop Proteins 0.000 abstract 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 abstract 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
600482 Disclosed is an in vitro method for diagnosing fibrosis comprising measuring the expression of Sprouty1 protein in a sample from a patient supposed to suffer from fibrosis; wherein a reduced level of Sprouty1 in comparison to a control sample indicates fibrosis or a predisposition thereof. Further disclosed is an in vitro method for screening a pharmaceutically active compound for the treatment and/or prevention of fibrosis or a predisposition thereof, comprising the steps of: a. contacting the candidate substance with a sample containing Sprouty1; b. determining the effect of the candidate substance on the sample; wherein an alteration of Sprouty1 indicates a pharmaceutically active compound. Further disclosed is an in vitro method for increasing Sprouty1 protein in a fibroblast comprising contacting the fibroblast with a compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the nuceobase sequence of the modified oligonucleotide is complementary to miR-21 or a precursor thereof, thereby stimulating Sprouty1 protein expression.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3183508P | 2008-02-27 | 2008-02-27 | |
| EP20080003570 EP2096171A1 (en) | 2008-02-27 | 2008-02-27 | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| US3334008P | 2008-03-03 | 2008-03-03 | |
| EP09051986 | 2009-02-19 | ||
| NZ588185A NZ588185A (en) | 2008-02-27 | 2009-02-26 | Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ600482A true NZ600482A (en) | 2013-11-29 |
Family
ID=49640278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ600482A NZ600482A (en) | 2008-02-27 | 2009-02-26 | Microrna (miRNA)and downstream targets for diagnostic and therapeutic purposes |
Country Status (3)
| Country | Link |
|---|---|
| NZ (1) | NZ600482A (en) |
| RS (1) | RS52904B (en) |
| ZA (1) | ZA201005998B (en) |
-
2009
- 2009-02-26 NZ NZ600482A patent/NZ600482A/en unknown
- 2009-02-26 RS RS20130340A patent/RS52904B/en unknown
-
2010
- 2010-08-23 ZA ZA2010/05998A patent/ZA201005998B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS52904B (en) | 2014-02-28 |
| ZA201005998B (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ588185A (en) | Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes | |
| Chiba et al. | Down-regulation of miR-133a contributes to up-regulation of Rhoa in bronchial smooth muscle cells | |
| Yu et al. | MicroRNAs regulate vascular smooth muscle cell functions in atherosclerosis | |
| US11185539B2 (en) | Natural compounds and fibrosis | |
| McMahon et al. | Regulation of the unfolded protein response by noncoding RNA | |
| Chaturvedi et al. | Epigenetic mechanisms underlying cardiac degeneration and regeneration | |
| Miao et al. | MicroRNA-152 modulates the canonical Wnt pathway activation by targeting DNA methyltransferase 1 in arthritic rat model | |
| WO2010103015A9 (en) | Microrna for diagnostic and therapeutic purposes in cardiovascular diseases | |
| NZ704322A (en) | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway | |
| Ujigo et al. | Administration of microRNA-210 promotes spinal cord regeneration in mice | |
| Ibrahim et al. | MicroRNA-dependent targeting of the extracellular matrix as a mechanism of regulating cell behavior | |
| WO2007137156A3 (en) | Rnai modulation of aha and therapeutic uses thereof | |
| Omran et al. | MicroRNAs: a new piece in the paediatric cardiovascular disease puzzle | |
| Mruthyunjaya et al. | c-Jun/AP-1 transcription factor regulates laminin-1-induced neurite outgrowth in human bone marrow mesenchymal stem cells: role of multiple signaling pathways | |
| Matsukura et al. | Overexpression of microRNA-155 suppresses chemokine expression induced by Interleukin-13 in BEAS-2B human bronchial epithelial cells | |
| Li et al. | RNA interfering connective tissue growth factor prevents rat hepatic stellate cell activation and extracellular matrix production | |
| Dang et al. | Suppression of TRIM8 by microRNA-182-5p restricts tumor necrosis factor-α-induced proliferation and migration of airway smooth muscle cells through inactivation of NF-Κb | |
| Srivastava et al. | Emerging role of MyomiRs as biomarkers and therapeutic targets in skeletal muscle diseases | |
| Wang et al. | Downregulation of lncRNA MIR181A2HG by high glucose impairs vascular endothelial cell proliferation and migration through the dysregulation of the miRNAs/AKT2 axis | |
| NZ600482A (en) | Microrna (miRNA)and downstream targets for diagnostic and therapeutic purposes | |
| US10881683B2 (en) | Nucleic acid molecule | |
| Zhang et al. | MicroRNA‑146a attenuates isoproterenol‑induced cardiac fibrosis by inhibiting FGF2 | |
| Formosa et al. | Salivary miRNAome profiling uncovers epithelial and proliferative miRNAs with differential expression across dentition stages | |
| Sun et al. | Epithelial-Mesenchymal transition and its regulation in tumor metastasis | |
| Benard | The Role of miRNA Families on the Regulation of Skeletal Muscle Mass and Function Throughout the Murine Lifespan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 FEB 2016 BY SPRUSON + FERGUSON Effective date: 20140407 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 FEB 2017 BY DENNEMEYER + CO Effective date: 20160122 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 FEB 2018 BY DENNEMEYER + CO. Effective date: 20170120 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 FEB 2019 BY DENNEMEYER + CO Effective date: 20180123 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 FEB 2020 BY CPA GLOBAL Effective date: 20190221 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 FEB 2021 BY CPA GLOBAL Effective date: 20200110 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 FEB 2022 BY CPA GLOBAL Effective date: 20210114 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 FEB 2023 BY CPA GLOBAL Effective date: 20220113 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 FEB 2024 BY CPA GLOBAL Effective date: 20230112 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 FEB 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240111 |